Role of Tissue-Type Plasminogen Activator in Ischemic Stroke
Tissue-type plasminogen activator (t-PA) administration has been approved for treating acute ischemic stroke, but delayed treatment is associated with increased risk of cerebral hemorrhage and brain injury. t-PA, a serine proteinase, converts plasminogen to plasmin. Plasmin participates not only in...
Saved in:
Main Author: | Yasuhiro Suzuki (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2010-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel Situations of Endothelial Injury in Stroke - Mechanisms of Stroke and Strategy of Drug Development: Intracranial Bleeding Associated With the Treatment of Ischemic Stroke: Thrombolytic Treatment of Ischemia-Affected Endothelial Cells With Tissue-Type Plasminogen Activator
by: Yasuhiro Suzuki, et al.
Published: (2011) -
The Utility of Automated ASPECTS in Acute Ischemic Stroke for Intravenous Recombinant Tissue Plasminogen Activator (IV-rtPA) Therapy
by: Soichiro Shibata, et al.
Published: (2022) -
Neutrophilic noncoding RNAs predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator
by: Ziping Han, et al.
Published: (2022) -
Does intravenous administration of recombinant tissue plasminogen activator for ischemic stroke can cause inferior myocardial infarction?
by: Mostafa Almasi, et al.
Published: (2016) -
QiShenYiQi Inhibits Tissue Plasminogen Activator-Induced Brain Edema and Hemorrhage after Ischemic Stroke in Mice
by: Yang Ye, et al.
Published: (2022)